Regulatory Pathway definition

Regulatory Pathway shall have the meaning provided in Section 5.2(d)(iii).

Examples of Regulatory Pathway in a sentence

  • Regulatory Pathway in AMLRationale for AMLThere is a clear unmet medical need in AML, with about 20,000 cases/year in the U.S. alone.

  • JJF Group Limited Liability Company Date: By: ------------------------- -------------------------------- Name: ------------------------------ Title: ----------------------------- -1- 21 EXHIBIT "B" ACCELERATED PUT NOTICE TO: Anker Coal Group, Inc.

  • US Proposals to Establish a Regulatory Pathway for FoPPsMembers of Congress and other policymakers have put forth various proposals for establishing a regulatory pathway for FoPPs. During the 110th Congress, five bills were introduced in the House and Senate and referred to committee.

  • Provide a Science-Based Regulatory Pathway to Streamline Animal Biotechnology Approvals Improved animal genetics is a critical tool as livestock producers work to adapt to a changing climate.

  • Chen, “Aggregating Automatically Extracted Regulatory Pathway Relations,” IEEE Transactions on Information Technology in Biomedicine, Volume 10, Number 1, Pages 100-108, 2006.

  • Policy D2: Define Regulatory Pathway for Redeveloping Surface Parking LotsThe prevalence of vacant and underutilized land within CBD of potential property tax revenue and contribute to the fiscal underperformance of this land.

  • Steady Focus on US Regulatory Pathway for The NGAL Test The NGAL Test is currently CE marked for measurement of NGAL in adults in the ICU and is available for IVD use in Europe and other geographies.

  • DermaSys® Regulatory Pathway As DermaSys® alone, without the inclusion of GTN has been shown, in the Board’s view, to be a highly effective and safe treatment for ED, Futura now plans to pursue the medical device regulatory pathway for its proprietary transdermal formulation DermaSys® in the US and Europe.

  • Impact of Trump Administration Regulatory Pathway Scenarios on GDP.

  • Novel MechanismLarge Market Potential for Social Anxiety DisorderCURRENT TREATMENTS FOR SOCIAL ANXIETY DISORDER DRUG FASTACTING Attractive Clinicalof Action Potential BNC210BNC210 IS DESIGNED TO PROVIDE POTENTIAL ADVANTAGES COMPARED TO CURRENT THERAPIES*Potential for Acute Treatment in Social Anxiety Disorder Patients& Regulatory Pathway Anti-Anxiety EffectsIn healthy subjects (anti-panic) and GAD patients (anti-anxiety)Rapid Onset of Action 1.

Related to Regulatory Pathway

  • Regulatory Documentation means, with respect to the Compounds, all submissions to Regulatory Authorities in connection with the development of such Compounds, including all INDs and amendments thereto, NDAs and amendments thereto, drug master files, correspondence with regulatory agencies, periodic safety update reports, adverse event files, complaint files, inspection reports and manufacturing records, in each case together with all supporting documents (including documents that include Clinical Data).

  • Regulatory Problem means any set of facts or circumstance wherein it has been asserted by any governmental regulatory agency (or a Regulated Stockholder reasonably believes that there is a risk of such assertion) that such Regulated Stockholder is not entitled to acquire, own, hold or control, or exercise any significant right (including the right to vote) with respect to, any Equity Securities of the Company or any subsidiary of the Company.

  • Development Application means the development application identified in Item 5 of Schedule 1 and includes all plans, reports models, photomontages, material boards (as amended supplemented) submitted to the consent authority before the determination of that Development Application.

  • Regulatory Materials means, with respect to a Licensed Product for any particular indication in any particular jurisdiction, regulatory applications and submissions (and any supplements or amendments thereto), and any notifications, communications, correspondence, registrations, drug master files, Regulatory Approvals and/or other filings made to, received from or otherwise conducted with a Regulatory Authority, including BLAs and INDs, as applicable, that relate to such Licensed Product in such jurisdiction. Regulatory Materials also include presentations, responses, and applications for Regulatory Approvals.

  • Regulatory Filing means any filing with any Governmental Authority with respect to the research, development, manufacture, distribution, pricing, reimbursement, marketing or sale of a Product.

  • Regulatory Floodway means the channel of a river or other watercourse and the adjacent land areas that must be reserved in order to discharge the base flood without cumulatively increasing the water surface elevation more than a designated height.

  • Regulatory Data means any and all research data, pharmacology data, chemistry, manufacturing, and control data, preclinical data, clinical data or all other documentation submitted, or required to be submitted, to Regulatory Authorities in association with regulatory filings for the Product in the Field (including any Drug Master Files (DMFs), Chemistry, Manufacturing and Control (“CMC”) data, or similar documentation).

  • Investigational Medicinal Product means the study drug or control material as defined in the Protocol.

  • Commercialization or “Commercialize” means activities directed to marketing, promoting, research and development as required, manufacturing for sale, offering for sale, distributing, importing or selling a product, including sub-licensing or sub-contracting of these activities.

  • Regulatory entity means any board, commission, agency,

  • Regulatory Filings means any submission to a Regulatory Authority of any appropriate regulatory application together with any related correspondence and documentation, and will include any submission to a regulatory advisory board, marketing authorization application, and any supplement or amendment thereto.

  • Investigational Product means the Study Drug identified above and the control material, as further detailed in the Protocol;

  • Commercializing means to engage in Commercialization and “Commercialized” has a corresponding meaning.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Manufacturing Know-How means, with respect to the Product or any Variant thereof, the technology, data, designs, processes, methods, specifications and other know-how used in connection with the formulation, manufacture, labeling, packaging, quality control, release testing, and production of the Product, and all ingredients used therein and portions thereof.

  • Regulatory Approval Application means any application submitted to an appropriate Regulatory Authority seeking any Regulatory Approval.

  • Regulatory Authority means any applicable supra-national, federal, national, regional, state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Exploitation of a Licensed Compound or a Licensed Product in the Territory.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Program Know-How means all Information and inventions that are conceived, discovered, developed, or otherwise made by or on behalf of either Party or its Affiliates or sublicensees in connection with the work conducted under or in connection with this Agreement.

  • Development Data means all non-clinical, clinical, technical, chemical, safety, and scientific data and information and other results, including relevant laboratory notebook information, screening data, and synthesis schemes, including descriptions in any form, data and other information, in each case, that is generated by or resulting from or in connection with the conduct of Development of Products, to the extent that the same are Controlled by or in Adapt’s or its Affiliates’ or Adapt’s Commercial Sublicensees’ possession, and may be disclosed to Lightlake without violating any obligation under Applicable Law.

  • Program Materials means the documents and information provided by the Program Administrator specifying the qualifying EEMs, technology requirements, costs and other Program requirements, which include, without limitation, program guidelines and requirements, application forms and approval letters.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Regulatory Authorities means the Commissions and the Exchange;

  • Third Party Materials means materials and information, in any form or medium, including any software, documents, data, content, specifications, products, equipment or components of or relating to the Services that are not proprietary to NCIT.

  • Regulatory Documents means the prospectus, annual report, semi-annual report and any other document required under applicable federal securities law to be delivered by the Trust to Fund shareholders.